UPDATE 1-Will Saudi Aramco deliver world record profit for next year's IPO?

* Valuation demands annual earnings around $130 billion (Adds latest figures for Aramco's reserves in paragraph 3)

from Reuters: New Issues News http://ift.tt/2wO9R22

CORRECTED-Will Saudi Aramco deliver world record profit for next year's IPO?

LONDON, Sept 8 (Reuters) - When oil giant Saudi Aramco discloses its financials for the first time next year, it must either surprise investors with world record profits or reduce its aspirations for a $2 trillion valuation in its initial public offering (IPO).

from Reuters: New Issues News http://ift.tt/2xTIX8P

Will Saudi Aramco deliver world record profit for next year's IPO?

LONDON, Sept 8 (Reuters) - When oil giant Saudi Aramco discloses its financials for the first time next year, it must either surprise investors with world record profits or reduce its aspirations for a $2 trillion valuation in its initial public offering (IPO).

from Reuters: New Issues News http://ift.tt/2eQSFUO

Fenergo hires 300 as banks step up mid-office overhaul

LONDON, Sept 7 (IFR) - Financial technology firm Fenergo is doubling its staff as banks sign up for its software to "onboard" clients and carry out compliance and due diligence more easily - further evidence of the technology shaking up capital markets.

from Reuters: New Issues News http://ift.tt/2eGOo2V

Syndicated sale of 50-year gilt attracts 2nd highest demand on record

LONDON, Sept 5 (Reuters) - Britain's sale via syndication of a 50-year government bond attracted the second highest amount of orders on record, the United Kingdom Debt Management Office (DMO) said on Tuesday.

from Reuters: New Issues News http://ift.tt/2eCe2FE

Britain sells 4.0 bln stg of 2065 gilt via syndication

LONDON, Sept 5 (Reuters) - Britain said on Tuesday that it had sold 4.0 billion pounds ($5.2 billion) of the 2.5 percent 2065 conventional gilt via syndication.

from Reuters: New Issues News http://ift.tt/2wCdART

Britain's Destiny Pharma raises cash to fund 'superbug' drugs

LONDON, Sept 4 (Reuters) - Britain's Destiny Pharma , which is developing drugs to target antibiotic-resistant bacterial infections, has raised 15.3 million pounds ($19.8 million) by listing shares on London's AIM market.

from Reuters: New Issues News http://ift.tt/2eVASZM